XML 15 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities    
Net loss $ (10,393,534) $ (7,279,781)
Adjustments to reconcile net loss to net cash used in operating activities    
Amortization of debt discount on notes payable 767,883 925,634
Amortization of investment premiums 49,282 85,011
Amortization of financing costs 519,960  
Amortization of non-cash clinical trial costs 399,587  
Change in fair value of debt conversion feature liability (848,374) (508,597)
Stock-based compensation 743,497 1,114,799
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 53,827 (16,098)
Accounts payable 57,153 402,448
Accrued expenses 1,168,957 (675,380)
Net cash used in operating activities (7,481,762) (5,951,964)
Cash flows from investing activities    
Purchases of investments (10,426,060) (10,246,479)
Proceeds from sales and maturities of investments 11,700,000 11,388,000
Net cash provided by investing activities 1,273,940 1,141,521
Cash flows from financing activities    
Proceeds from issuances of common stock, net of underwriting discounts and commissions 6,582,278 9,918,750
Public offering and financing costs (62,045) (609,250)
Repayment of convertible notes payable   (94,861)
Value of shares withheld related to employee tax withholding (13,871) (23,759)
Proceeds from stock issuance under employee stock purchase plan 19,609 10,943
Net cash provided by financing activities 6,525,971 9,201,823
Net increase in cash and cash equivalents 318,149 4,391,380
Cash and cash equivalents beginning of period 3,075,502 768,550
Cash and cash equivalents end of period 3,393,651 5,159,930
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest   205,139
Supplemental disclosure of non-cash investing and financing transactions    
Shares issued to cover future clinical trial costs 1,800,000  
Unpaid deferred public offering and other financing costs $ 147,804 381,991
Shares issued in lieu of loan payment to related party   $ 1,200,000